We love to hear from our listeners. Send us a message.
BlueSphere Bio's CEO Dr. David Apelian explains the difficulties associated with treating solid tumor cancers as well as what the CGT sector needs to get right in the short term and why.
Subscribe to the podcast!Apple | Spotify | YouTube
Visit my website: Cell & Gene
Connect with me on LinkedIn
Cell & Gene: The Podcast